Short text messages helped GLP-1 drug users build healthier habits in a two-week trial

GLP-1 receptor agonists like semaglutide and tirzepatide are transforming weight management. But a drug that suppresses appetite does not, on its own, teach someone to exercise regularly, eat differently, or build the habits that sustain weight loss after treatment ends. A new randomized clinical trial asks whether something as simple as text-based behavioral prompts could help fill that gap.

Microsteps, not grand plans

The trial, published in JAMA Network Open, tested a low-cost digital intervention in adults already taking GLP-1 receptor agonists (GLP-1RAs). The intervention consisted of written "microsteps," small, specific behavioral prompts, supplemented by short video boosters. The concept is deliberately modest: rather than asking participants to overhaul their routines, microsteps propose one small action at a time.

The primary outcome was not behavior change itself but expectation to adopt health behaviors, a psychological precursor that predicts whether people actually follow through. The trial found that the intervention group showed increased behavioral expectations compared to controls, and the effect persisted for at least two weeks.

Why expectations matter

Behavioral science has established that a person's expectation of performing a behavior is one of the strongest predictors of whether they actually do it. This is particularly relevant for GLP-1RA users, who face a well-documented challenge: when they stop taking the drug, weight regain is common. Building behavioral habits while the pharmacological support is active could theoretically improve long-term outcomes, though this study did not test that hypothesis directly.

The trial was designed as a proof of concept. It demonstrates that a scalable, inexpensive digital tool can shift the psychological groundwork for behavior change in this population. Whether the behavioral expectations translate into sustained action, and whether that action improves weight maintenance, are questions for longer follow-up studies.

Scalability as a feature

The intervention's low cost and digital delivery are central to its potential value. GLP-1RAs are expensive medications, and the populations using them are large and growing. Intensive behavioral counseling, while effective, is resource-heavy and difficult to scale. A text-based supplement that can be delivered automatically to thousands of users simultaneously represents a different category of intervention, one that could operate as a standard adjunct to pharmacotherapy if longer trials confirm its benefits.

What the trial does not answer

The study measured expectations, not actions. Two weeks is enough to detect a shift in mindset but not enough to determine whether that shift produces lasting behavioral change. The researchers acknowledge this limitation directly and call for longer trials to bridge the gap between intention and sustained behavior.

The sample characteristics, specific drug regimens, and details of the microsteps content are available in the full publication. The trial was led by Maya Adam, MD, PhD, at Stanford University.